Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis

Grundmark, Birgitta (author): Uppsala universitet,Institutionen för medicinska vetenskaper,Cancer Pharmacology and Informatics/Rolf Larsson

Tholander, B. (author)

Glimelius, Bengt (author): Karolinska Institutet,Uppsala universitet,Enheten för onkologi,GI

Larsson, Rolf (author): Uppsala universitet,Klinisk farmakologi,Clinical Pharmacology and Informatics

(creator_code:org_t)

Elsevier BV, 2008
2008
English.
In: European Journal of Surgical Oncology. - : Elsevier BV. - 0748-7983 .- 1532-2157. ; 34:5, s. 547-552

Related links:: https://urn.kb.se/re...; show more...; https://doi.org/10.1...; http://kipublication...; show less...

Abstract Subject headings

AIMS: To investigate if the pattern of cytotoxic drug sensitivity in vitro in patient samples of peritoneal carcinomatosis (PC) is supportive to the current standardized approach for drug selection for perioperative intraperitoneal chemotherapy (IPC). METHODS: The cytotoxic effect of cisplatin, oxaliplatin, irinotecan, 5-fluorouracil, mitomycin-C, doxorubicin and melphalan was investigated in vitro on tumour cells from 223 patient tumour samples of different PC origins. RESULTS: Considerable differences in cytotoxic drug sensitivity between tumour types of the PC entity and within each tumour type were observed. Cisplatin showed high cross-resistance with oxaliplatin but low cross-resistance with doxorubicin and irinotecan. No cross-resistance was found between irinotecan and doxorubicin. The dose-response relationships for melphalan and irinotecan in individual samples showed great variability. CONCLUSIONS: The activity in vitro of cytotoxic drugs commonly used in IPC for PC is very heterogeneous. Efforts for individualizing drug selection for PC patients undergoing IPC seem justified.

By the author/editor: Mahteme, Haile; von Heideman, An ...; Grundmark, Birgi ...; Tholander, B.; Påhlman, Lars; Glimelius, Bengt; show more...; Larsson, Rolf; Graf, Wilhelm; Nygren, Peter; show less...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.